Ipamorelin Research & Studies
Part of the full Ipamorelin guide - a selective growth-hormone secretagogue reference compound, identity-verified with a COA on every vial.
In brief
This spoke summarizes what the cited literature and the listed research areas investigate for ipamorelin, attributed strictly to the single source provided in the entry. The data lists three research areas and one primary citation. Nothing here extends beyond those provided references, and no additional studies, numbers, or claims are introduced.
The detail
A closer look
01
The primary cited source
The entry's sole citation is Raun, K., et al. (1998), 'Ipamorelin, the first selective growth hormone secretagogue,' published in the European Journal of Endocrinology (DOI 10.1530/eje.0.1390552; PMID 9849822). The title itself frames the central research finding attributed to this work: ipamorelin's status as a selective growth-hormone secretagogue. This source is cited in the keyFacts as the basis for two facts in particular: the receptor identity (GHS-R1a / ghrelin) and the selectivity profile (GH release without an accompanying ACTH/cortisol/prolactin rise). All receptor and selectivity statements in this reference set trace to this 1998 source.
02
Research area 1: receptor-binding and selectivity assays
The first listed research area is 'GHS-R1a receptor-binding and selectivity assays.' This describes laboratory work that characterizes how the peptide binds the GHS-R1a (ghrelin) receptor and how selective that engagement is. In the context of the cited source, this is the body of investigation that establishes ipamorelin as a GHS-R1a agonist and quantifies its selectivity relative to other receptor outputs. These are binding- and receptor-level assays, not organismal outcome studies.
03
Research area 2: somatotroph calcium-signaling and GH-secretion models
The second research area is 'Somatotroph calcium-signaling and GH-secretion models.' This corresponds to the cell-model work that traces the post-binding cascade described in the mechanism data: the Gq/11-PLC-IP3-calcium pathway and the resulting exocytosis of growth-hormone vesicles from somatotrophs. Research in this area uses pituitary somatotroph model systems to observe calcium signaling and growth-hormone release as the functional readout of receptor activation.
04
Research area 3: comparative secretagogue pharmacology
The third research area is 'Comparative secretagogue pharmacology (cortisol/prolactin selectivity).' This is the comparative-pharmacology work that places ipamorelin against earlier secretagogues, specifically examining whether growth-hormone release occurs without proportional ACTH, cortisol, and prolactin elevation. This is the experimental context in which the selectivity claim attributed to Raun et al. 1998 was established, and it is the basis for the entry describing selectivity as the peptide's defining research feature. As the entry states explicitly, reported activity is mechanistic and model-system based; no human dosing, therapeutic, or outcome claim is made.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Ipamorelin is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.